{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:09:29Z","timestamp":1769594969657,"version":"3.49.0"},"reference-count":108,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2008,4,28]],"date-time":"2008-04-28T00:00:00Z","timestamp":1209340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In patients with squamous cell carcinoma of the head and neck (SCCHN), tumor recurrence, secondary tumors, and comorbidities contribute to therapy failure, and treatment approaches often are limited by their toxicity. With the incorporation of targeted therapies, the number of options available for patients with SCCHN is growing. The epidermal growth factor receptor (EGFR) is involved in the development and progression of SCCHN and is associated with a poor prognosis. The anti\u2010EGFR monoclonal antibody (MoAb) cetuximab is the first targeted therapy to be developed for SCCHN. Recent data confirmed a survival advantage and enhanced locoregional control of SCCHN with cetuximab plus radiotherapy (RT) in patients with locally advanced (LA) SCCHN. Single\u2010agent cetuximab conferred clinical benefits for patients with platinum\u2010refractory metastatic disease, and a recent phase 3 trial demonstrated a survival benefit with cetuximab and standard platinum\u2010based therapy in the front\u2010line treatment of recurrent\/metastatic disease. Cetuximab has a toxicity profile milder than that of cytoxic agents and does not exacerbate RT toxicity when it is used in combination. Small\u2010molecule EGFR\u2010tyrosine kinase inhibitors also have shown promise in combination with chemoradiotherapy or as single agents, although they are in earlier stages of developmental. Other targeted approaches (eg, antiangiogenics) are also under investigation. Ongoing clinical trials will further define targeted treatment roles in all stages of SCCHN. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.23521","type":"journal-article","created":{"date-parts":[[2008,4,28]],"date-time":"2008-04-28T17:19:57Z","timestamp":1209403197000},"page":"2635-2645","source":"Crossref","is-referenced-by-count":46,"title":["Targeted therapy in head and neck cancer"],"prefix":"10.1002","volume":"112","author":[{"given":"Corey J.","family":"Langer","sequence":"first","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2008,4,28]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:23:1:1"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90938-7"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.147"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)03792-6"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.021"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.060"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh306"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.119"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1088"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.257"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.057"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.008"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031317"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.193"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.10.076"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01544-9"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)90011-4"},{"key":"e_1_2_10_19_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.90140.5505","article-title":"Update of MACH\u2010NC (Meta\u2010Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy","volume":"22","author":"Bourhis J","year":"2004","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032646"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032641"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01826-0"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69121-6"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-004-0001-y"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.4.3.200"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.09.059"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21284"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70757-4"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70860-9"},{"key":"e_1_2_10_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf268"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.1990"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070956"},{"issue":"18","key":"e_1_2_10_33_2","article-title":"A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5\u2010fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN): final analysis of EORTC 24971","volume":"24","author":"Remenar E","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_34_2","article-title":"A phase III randomized trial of docetaxel\u2010based induction chemotherapy in patients with N2\/N3 locally advanced head and neck cancer (DeCIDE Trial)","author":"Cohen EEW","year":"2007","journal-title":"Protocol identifier NCT0011 7572."},{"key":"e_1_2_10_35_2","unstructured":"KhuriF; for the Dana\u2010Farber Cancer Institute. The Paradigm Trial. A randomized phase III trial comparing sequential therapy with TPF\/chemoradiation (ST) to cisplatin\u2010based chemoradiotherapy with accelerated concomitant boost radiotherapy (CRT) for locally advanced squamous cell cancer of the head and neck. Study DFCI1015\u201004; protocol 07182005.Available at:http:\/\/cancer.emory.edu\/clinical\/trialdetail.php?id=723&detail=full. Accessed July 10 2007."},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-200039628"},{"key":"e_1_2_10_37_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.5505","article-title":"Cetuximab in recurrent\/metastatic squamous cell carcinoma of the head and neck refractory to first\u2010line platinum\u2010based therapies","volume":"23","author":"Vermorken J","year":"2005","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi452"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.14.3333"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/153303460200100206"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.7851"},{"key":"e_1_2_10_42_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.6.11.1539"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.5.8.1085"},{"key":"e_1_2_10_44_2","first-page":"3579","article-title":"Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer","volume":"53","author":"Grandis JR","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_10_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00714485"},{"key":"e_1_2_10_46_2","first-page":"3579","article-title":"Elevated levels of transforming growth factor and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer","volume":"53","author":"Grandis JR","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.8306"},{"key":"e_1_2_10_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00511-X"},{"key":"e_1_2_10_49_2","first-page":"7350","article-title":"Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma","volume":"62","author":"Ang KK","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_10_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2004.09.011"},{"key":"e_1_2_10_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.10.014"},{"key":"e_1_2_10_52_2","first-page":"701","article-title":"Enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody","volume":"6","author":"Milas L","year":"2000","journal-title":"Clin Cancer Res."},{"key":"e_1_2_10_53_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.04.003"},{"key":"e_1_2_10_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl235"},{"key":"e_1_2_10_55_2","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang SM","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_10_56_2","first-page":"2166","article-title":"Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesis","volume":"6","author":"Huang S\u2010M","year":"2000","journal-title":"Clin Cancer Res."},{"key":"e_1_2_10_57_2","first-page":"507","article-title":"Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade","volume":"1","author":"Huang S\u2010M","year":"2002","journal-title":"Mol Cancer Ther."},{"key":"e_1_2_10_58_2","doi-asserted-by":"publisher","DOI":"10.2174\/156800906779010191"},{"key":"e_1_2_10_59_2","first-page":"1311","article-title":"Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model","volume":"1","author":"Goldstein NI","year":"1995","journal-title":"Clin Cancer Res."},{"key":"e_1_2_10_60_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M506591200"},{"key":"e_1_2_10_61_2","unstructured":"HadariYR DoodyJF WangY et al.The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor[abstract]. Presented at the 2004 Gastrointestinal Cancers Symposium San Francisco California January22\u201324 2004. Abstract 234."},{"key":"e_1_2_10_62_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199611000-00006"},{"key":"e_1_2_10_63_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1999.14.451"},{"key":"e_1_2_10_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.08.035"},{"key":"e_1_2_10_65_2","first-page":"4322","article-title":"Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti\u2010epidermal growth factor receptor monoclonal antibodies","volume":"53","author":"Fan Z","year":"1993","journal-title":"Cancer Res."},{"key":"e_1_2_10_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01518458"},{"key":"e_1_2_10_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22370"},{"key":"e_1_2_10_68_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"e_1_2_10_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7595"},{"key":"e_1_2_10_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422"},{"key":"e_1_2_10_71_2","unstructured":"Food & Drug Administration Press Release. FDA approves first head & neck cancer treatment in 45 years: data show treatment with Erbitux extends survival. FDA News. March 1 2006. Available at:http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2006\/NEW01329.html. Accessed July 11 2007."},{"key":"e_1_2_10_72_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.00.1792"},{"key":"e_1_2_10_73_2","unstructured":"SuntharalingamM TaylorR WolfJ et al.Initial report of phase II trial of weekly cetuximab CBDCA paclitaxel and daily RT in patients with locally advanced SCCHN[abstract]. Presented at the Multidisciplinary Head and Neck Cancer Symposium cosponsored by the American Society for Therapeutic Radiology and Oncology and the American Society of Clinical Oncology Rancho Mirage California January18\u201320 2007. Abstract 5."},{"key":"e_1_2_10_74_2","unstructured":"National Library of Medicine. Search results for various head and neck cancer trials (RTOG\u20100522 RTOG\u20100234 ECOG\u20103303 ECOG\u2010E2303 and keywords bevacizumab\/cetuximab bevacizumab\/chemoradiotherapy). Available at:http:\/\/www.clinicaltrials.gov\/. Accessed July 11 2007."},{"key":"e_1_2_10_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7447"},{"key":"e_1_2_10_76_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.120"},{"key":"e_1_2_10_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.4646"},{"key":"e_1_2_10_78_2","article-title":"Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy: results of a randomized phase III (EXTREME) study","volume":"25","author":"Vermorken J","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(98)00050-3"},{"key":"e_1_2_10_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600299"},{"key":"e_1_2_10_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11437"},{"key":"e_1_2_10_82_2","first-page":"501s","article-title":"Integration of gefitinib into a concurrent chemoradiation regimen followed by gefitinib adjuvant therapy in patients with locally advanced head and neck cancer\u2014a phase II trial","volume":"24","author":"Cohen EE","year":"2005","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_10_83_2","article-title":"Induction chemotherapy + gefitinib followed by concurrent chemotherapy\/radiation therapy\/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a phase I\/II trial of the Minnie Pearl Cancer Research Network","volume":"24","author":"Doss HH","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_84_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.5575","article-title":"Phase I\/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)","volume":"24","author":"Herchenhorn D","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_85_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.5553","article-title":"A phase I, open\u2010label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)","volume":"24","author":"Harrington KJ","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_86_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.5545","article-title":"Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN)","volume":"24","author":"Savvides P","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_87_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.051"},{"key":"e_1_2_10_88_2","article-title":"Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN)","volume":"22","author":"Kane MA","year":"2004","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_89_2","first-page":"507s","article-title":"Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca)","volume":"24","author":"Wheeler RH","year":"2005","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_10_90_2","first-page":"225a","article-title":"Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"21","author":"Cohen EEW","year":"2002","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_10_91_2","unstructured":"Health Canada\/AstraZeneca. December 1 2006 letter to healthcare professionals. Health Canada endorsed important safety information on Iressa (gefitinib): lack of survival benefit and increased incidence of tumour haemorrhage in association with IRESSA\u00ae in patients with squamous cell carcinoma of the head and neck (SCCHN). Available at:http:\/\/www.hc\u2010sc.gc.ca. Accessed July 11 2007."},{"key":"e_1_2_10_92_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.5563","article-title":"Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and\/or metastatic squamous\u2010cell carcinoma of the head and neck","volume":"23","author":"Belon J","year":"2005","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_93_2","article-title":"Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent\/metastatic head and neck cancer","volume":"25","author":"Kim ES","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_94_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.4182"},{"key":"e_1_2_10_95_2","article-title":"A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck","volume":"24","author":"Vokes EE","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_96_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.5568","article-title":"A phase II study of lapatinib (GW572016) in recurrent\/metastatic squamous cell carcinoma of the head and neck","volume":"24","author":"Abidoye OO","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_97_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.10.088"},{"key":"e_1_2_10_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1381"},{"key":"e_1_2_10_99_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104819"},{"key":"e_1_2_10_100_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_10_101_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.098"},{"key":"e_1_2_10_102_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_10_103_2","article-title":"Concurrent chemotherapy practice patterns for head and neck cancer: what is standard of care [abstract]?","volume":"24","author":"Wong SJ","year":"2006","journal-title":"J Clin Oncol."},{"key":"e_1_2_10_104_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920601)69:11<2744::AID-CNCR2820691119>3.0.CO;2-U"},{"key":"e_1_2_10_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(97)01904-X"},{"key":"e_1_2_10_106_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2273.2004.00897.x"},{"key":"e_1_2_10_107_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-006-1039-1"},{"key":"e_1_2_10_108_2","first-page":"282s","article-title":"EGFr expression and clinical outcome in head and neck cancer patients treated with radiotherapy with or without cetuximab","volume":"24","author":"Bonner JA","year":"2006","journal-title":"Proc Am Soc Clin Oncol."},{"key":"e_1_2_10_109_2","article-title":"Induction chemotherapy with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck","volume":"24","author":"Kies MS","year":"2006","journal-title":"J Clin Oncol."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23521","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23521","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:04:47Z","timestamp":1760267087000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23521"}},"subtitle":["State of the art 2007 and review of clinical applications"],"short-title":[],"issued":{"date-parts":[[2008,4,28]]},"references-count":108,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,6,15]]}},"alternative-id":["10.1002\/cncr.23521"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23521","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,28]]}}}